Article Sidebar

PDF
Date Published: 23/09/2022
Abstract Views: 214
Views PDF: 129
DOI: https://doi.org/10.51298/vmj.v518i1.3310
Issue
Vol. 518 No. 1 (2022)
Section
Các bài báo
How to Cite
Quang Duy, N. ., Xuân Huy, V. ., & Văn Xuân, V. . (2022). RESULTS OF TECHNICAL RADIOTHERAPY VMAT COMBINEĐAD WITH CHEMOTHERAPY WITH PACLITAXEL - CARBOPLATIN REGIMENS IN THE UPPER THIRD OF ESOPHAGEAL CANCER AT THE K HOSPITAL. Vietnam Medical Journal, 518(1). https://doi.org/10.51298/vmj.v518i1.3310

RESULTS OF TECHNICAL RADIOTHERAPY VMAT COMBINEĐAD WITH CHEMOTHERAPY WITH PACLITAXEL - CARBOPLATIN REGIMENS IN THE UPPER THIRD OF ESOPHAGEAL CANCER AT THE K HOSPITAL

Nguyễn Quang Duy1,, Vũ Xuân Huy1, Võ Văn Xuân1
1 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objective: Evaluation of the results of technical radiotherapy VMAT combinedad with chemotherapy with paclitaxel - carboplatin regimens in the upper third of esophageal cancer at the K hospital. Method: An uncontrolled clinical intervention study was performed on 51 patients with esophageal cancer from August 2021 to July 2022. Results: 100% of patients responded to treatment, of which complete response was 45.1%. In terms of clinical improvement, the majority of patients had a complete response (70.6%). Undesirable effects during chemotherapy are common such as decreased hemoglobin (9.8%), leukopenia (15.4%), hepatotoxicity (13.7%), and nephrotoxicity (17.6%). Effects on other organs such as nausea (27.4%), vomiting (13.7%), stomatitis (5.9%), hair loss (39.1%). Undesirable effects during radiation therapy such as radiation esophagitis (86.3%), dermatitis (76.5%). Conclusion: This treatment regimen should be applied more commonly in the treatment of esophageal cancer due to its safety and good response.

Article Details

Keywords

Esophageal cancer, Paclitaxel-Carboplatin, chemotherapy, radiation therapy

References

1. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021. 71(3): p. 209-249.
2. International Agency for Research on Cancer, VietNam - Global Cancer Observatory. 2020.
3. Keresztes, R.S., et al., Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. The Journal of Thoracic and Cardiovascular Surgery, 2003. 126(5): p. 1603-1608.
4. Zhang, W.Z., et al., Volumetric modulated arc therapy vs. c-IMRT for the treatment of upper thoracic esophageal cancer. PLoS One, 2015. 10(3): p. e0121385.
5. Jin, X., et al., CRT combined with a sequential VMAT boost in the treatment of upper thoracic esophageal cancer. J Appl Clin Med Phys, 2013. 14(5): p. 153-61.
6. Li, Q.Q., et al., Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus, 2010. 23(3): p. 253-9.
7. Ohtsu, A., et al., Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol, 1999. 17(9): p. 2915-21.
8. Ishida, K., et al., Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol, 2004. 34(10): p. 615-9.
9. Nguyễn Đức Lợi, Đánh giá hiệu quả phác đồ hoá xạ trị đồng thời và một số yếu tố tiên lượng ung thư biểu mô thực quản giai đoạn III, IV tại bệnh viện K, Luận án tiến sĩ y học. 2015, Đại học Y Hà Nội.